Ignite Creation Date:
2024-05-06 @ 3:08 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04535882
Status:
RECRUITING
Last Update Posted:
2024-02-23
First Post:
2020-08-28
Brief Title:
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
Sponsor:
Showa Inan General Hospital
Organization:
Showa Inan General Hospital
Study Overview
Official Title:
Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohns Disease Colitis
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein LRG levels and endoscopic activity in patients with possible ulcerative colitis UC or Crohns disease CD to determine whether LRG was a predicting marker for UC or CD
Detailed Description:
Serum samples were collected from patients and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients Serum sampling and colonoscopy with histology were performed within 7 daysThe disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index CDAI respectively The Mayo endoscopy score was evaluated UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group
CD patients whose CDAI 150 were divided into the active CD group
CD patients whose CDAI 150 were divided into the active CD group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None